Compare LZM & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZM | AVXL |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | Isle of Man | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.0M | 397.6M |
| IPO Year | N/A | N/A |
| Metric | LZM | AVXL |
|---|---|---|
| Price | $3.73 | $4.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $10.50 | ★ $22.00 |
| AVG Volume (30 Days) | 149.7K | ★ 4.3M |
| Earning Date | 08-11-2025 | 11-25-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $416,323.00 | N/A |
| Revenue This Year | $611.56 | N/A |
| Revenue Next Year | $445.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.90 | $2.86 |
| 52 Week High | $7.29 | $14.44 |
| Indicator | LZM | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 36.78 | 37.24 |
| Support Level | $3.68 | $3.62 |
| Resistance Level | $4.04 | $4.88 |
| Average True Range (ATR) | 0.21 | 0.42 |
| MACD | 0.05 | 0.23 |
| Stochastic Oscillator | 14.61 | 57.56 |
Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining and to become an emerging supplier of responsibly sourced, lower-carbon and lower-sulfur dioxide emission metals to the battery, EV, and hydrogen markets modern pre-development exploration-stage metals company. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.